TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression.
Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, Sun J, Yang Q, Zhang X, Lu B. · 2012
Read TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. by Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, Sun J, Yang Q, Zhang X, Lu B. (2012) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3281852.txt.
Introduction
Xin Gao and colleagues characterized a checkpoint molecule on immune cells inside lung tumors, in this 2012 paper in PLoS ONE. TIM-3 is a brake on T cells, known to mark exhausted killer cells in chronic infection and cancer. What it does on the helper T cells infiltrating tumors was unclear, so the team analyzed immune cells from fifty-one patients with non-small cell lung cancer.
TIM-3 was strongly raised on both helper and killer T cells inside tumors but barely present on the same patients' blood cells. Killer cells carrying it made less of an antiviral cytokine. Most strikingly, about seventy percent of the TIM-3-carrying helper cells were regulatory T cells. These are the suppressors of immune attack. TIM-3 levels on helper cells also tracked with lymph node spread and advanced stage. The authors cast TIM-3 as a regulator acting mainly through these regulatory cells.
Catalog record
| CREATOR | Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, Sun J, Yang Q, Zhang X, Lu B. |
|---|---|
| YEAR | 2012 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression By Xin Gao, Yibei Zhu, Gang Li, Haitao Huang, Guangbo Zhang, Fengming Wang, Jing Sun, Qianting Yang, Xueguang Zhang, Binfeng Lu, Michael P Bachmann Published in: PLoS ONE DOI: 10.1371/journal.pone.0030676 ABSTRACT Abstract Background T cell immunoglobulin-3 (TIM-3) has been established as a negative regulatory molecule and plays a critical role in immune tolerance. TIM-3 is upregulated in exhausted CD8+ T cells in both chronic infection and tumor. However, the nature of TIM-3+CD4+ T cells in the tumor microenvironment is unclear. This study is to characterize TIM-3 expressing lymphocytes within human lung cancer tissues and establish clinical significance of TIM-3 expression in lung cancer progression. Methodology A total of 51 human lung cancer tissue specimens were obtained from pathologically confirmed and newly diagnosed non-small cell lung cancer (NSCLC) patients. Leukocytes from tumor tissues, distal normal lung tissues, and peripheral blood mononuclear cells (PBMC) were analyzed for TIM-3 surface expression by flow cytometry. TIM-3 expression on tumor-infiltrating lymphocytes (TILs) was correlated with clinicopathological parameters. Conclusions TIM-3 is highly upregulated on both CD4+ and CD8+ TILs from human lung cancer tissues but negligibly expressed on T cells from patients' peripheral blood. Frequencies of IFN-γ+ cells were reduced in TIM-3+CD8+ TILs compared to TIM-3−CD8+ TILs. However, the level of TIM-3 expression on CD8+ TILs failed to associate with any clinical pathological parameter. Interestingly, we found that approximately 70% of TIM-3+CD4+ TILs expressed FOXP3 and about 60% of FOXP3+ TILs were TIM-3+. Importantly, TIM-3 expression on CD4+ T cells correlated with poor clinicopathological parameters of NSCLC such as nodal metastasis and advanced cancer stages. Our study reveals a new role of TIM-3 as an important immune regulator in the tumor microenvironment via its predominant expression in regulatory T cells. INTRODUCTION Tumor development induces antitumor immune responses. Type 1 adaptive immune responses, mediated by Th1 cells and CTLs, are thought to be a critical component of cell-mediated immunity against cancer [1]. It has been well established, however, that many tumor infiltrating T cells are in a state of non-responsiveness due to the immune suppressive tumor microenvironment [2], [3]. Regulatory T cells and exhaustion of effector T cells are thought to be two main T cell intrinsic mechanisms that render ineffective anti-tumor immune responses [2], [4], [5]. Multiple molecular pathways, such as TGFβ, IL-10, members of B7 family, are involved in establishing the state of immune suppression within tumor [2], [6], [7], [8]. Understanding of the role of novel immune inhibitory pathways in mediating immune tolerance in the tumor microenvironment should help improving immunotherapy of cancer. TIM-3 is expressed on Th1, Th17 cells, and CD8 T cells, but not Th2 cells [9], [10], [11]. Interaction between TIM-3 and its ligand galectin-9 inhibits Th1 and Th17 responses [12] and induces peripheral tolerance [13], [14], supporting an inhibitory role of TIM-3 in T cell responses. TIM-3 expression also identifies exhausted T cells during chronic infection. TIM-3-expressing CD4+ and CD8+ T cells produce reduced amounts of cytokine or are less proliferative in response to antigen. Blockade of the TIM-3 signaling pathway restores proliferation and enhances cytokine production in HIV-1-specific T cells [15]. Recent studies have supported an important role of TIM-3 T cell exhaustion in cancer. Tim-3 and PD-1, another marker of T cell exhaustion, are co-expressed on CD8 TILs in mice bearing transplanted tumors as well as on NY-ESO-1-specific CD8+ T cells in patients with advanced melanoma [4], [5]. TIM-3+PD-1+ T cells exhibit the most severe exhausted phenotype as defined by failure to proliferate and produce IL-2, TNF, and IFN-γ. Blockade of both Tim-3 and PD-1 pathways is more effective in controlling tumor growth than targeting either pathway alone, suggesting these two pathways work synergistically in establishing T cell exhaustion [4], [5]. In this study, we have investigated TIM-3 expression in TILs in none small cell lung cancer (NSCLC). We have found that TIM-3 is expressed in both CD4+ and CD8+ TILs in lung cancer tissues. Both TIM-3+CD4+ and TIM-3+CD8+ T cells produced much reduced levels of IFN-γ compared to those in TIM-3−CD4+ and TIM-3−CD8+ T cells respectively. Interestingly, TIM-3 expression on CD4+ T cells but not CD8+ T cells correlated with poor clinicopathological parameters of NSCLC such as nodal metastasis and advanced cancer stages. Strikingly, approximately 70% of TIM-3+CD4+ TILs expressed FOXP3 and about 60% of FOXP3+ TILs were TIM-3+. In contrast, TIM-3 was minimally expressed in peripheral CD4+ T cells, Tregs, and CD8+ T cells. These data suggest a novel role of TIM-3 in tumor associated regulatory T cells and its importance in human cancer progression. MATERIALS AND METHODS Selection of tissue samples A total of 51 lung cancer tissue specimens were obtained from pathologically confirmed and newly diagnosed non-small cell lung cancer (NSCLC) patients who received operation from Oct. 2009 to May 2011 in Cardiothoracic Surgery Department of First Affiliated Hospital, Soochow University in the present study. In addition, 51 cases of adjacent normal tissues from non-malignant portion were resected and chosen as controls. The normal tissues were at least 5 centimeters away from the visible tumor mass. Autologous peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by Ficoll density gradient centrifugation before operation. This study was approved by the ethics committee of the First Affiliated Hospital of Soochow University. The data were analyzed anonymously and informed consent was not required. Harvest of tumor infiltrating lymphocytes (TILs) Tumor tissue and adjacent normal tissue from the same patient were minced and digested with collagenase digestion solution (1 mg/ml collagenase IV (Sigma-Aldrich, St. Louis, MO, USA) in RPMI1640) at 37°C for 45 min. The pieces were then transferred to the steel mesh and single cell suspensions were obtained by mechanical grind. TILs were further purified by the gradient as per manufacturer protocol, washed and re-suspended in Hank's media for various analyses. Mice 6–8-week-old female C57BL/6 mice were used in tumor experiments. All animals were maintained under specific pathogen-free conditions in the animal facility at the University of Pittsburgh or Soochow University. All animal work has been approved by the Institution Animal Care and Use Committee at the University of Pittsburgh (protocol number 0906824). For tumor model experiments, mice were challenged with 2×105 B16F0 cells i.d. and tumor samples were removed for analysis around day 20 as described previously [16]. In vitro T cell stimulation Naive T cells were purified from PBMCs of healthy donors using depleting anti-CD45RO antibody and Stemsep® human T cell enrichment kit (StemCell technologies, Vancouver, British Columbia, Canada). The purity of T cells was more than 90%. Cells were stimulated with 1 µg/ml plate-bound anti-CD3 (clone OKT3) and 2 µg/ml plate-bound anti-CD28 mAbs for up to 72 hours. For isolating Tregs, PBMCs were stained with phycoerythrin-cyanine Dye7 (PECY7) conjugated anti-CD4 mAb (RPA-T4) and anti-CD25 phycoerythrin (PE) (BC96). A MoFlo cytometer (Beckman-Coulter, Brea, CA USA) was used to isolate CD4+CD25high cells. These cells were then stimulated with anti-CD3 (1 µg/ml) and anti-CD28 (2 µg/ml) in the presence of IL-2 (200 U/mL, R&D Systems, Minneapolis, MN, USA). 24, 48, and 72 hours later, cells were harvested for further analysis. Antibodies and Flow Cytometric Analysis Directly conjugated anti-human antibodies against the following surface molecules were used: anti-CD4 (RPA-T4) and anti-CD8